The document discusses Emmanuelle Charpentier, who co-discovered CRISPR-Cas9 and is the founder of ERS Genomics. ERS Genomics holds patents for the foundational CRISPR-Cas9 technology and provides licenses to allow its use. The document outlines the patent portfolio and fields ERS Genomics provides licenses for, including research, therapeutics, agriculture, and more. Financial terms for licenses vary depending on factors like field of use, company size, and whether for internal research or commercial applications. Simplified terms are proposed for US academic institutions.